Obinutuzumab

Obinutuzumab
Monoclonal antibody
Type	Whole antibody
Source	Humanized (from mouse)
Target	CD20
Clinical data
Trade names	Gazyva, Gazyvaro
Other names	afutuzumab, GA101
AHFS/Drugs.com	Monograph
License data	EU EMA: by INN; US DailyMed: Obinutuzumab;
Pregnancy; category	AU: C;
Routes of; administration	Intravenous infusion
ATC code	L01FA03 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); US: WARNINGRx-only; EU: Rx-only;
Pharmacokinetic data
Elimination half-life	28.4 days
Identifiers
CAS Number	949142-50-1 ;
DrugBank	DB08935 ;
ChemSpider	none;
UNII	O43472U9X8;
KEGG	D09321 ;
Chemical and physical data
Formula	C6512H10060N1712O2020S44
Molar mass	146064.72 g·mol−1
	(what is this?) (verify)

Obinutuzumab, sold under the brand name Gazyva among others, is a humanized anti-CD20 monoclonal antibody used as a treatment for cancer. It was originated by GlycArt Biotechnology AG and developed by Roche.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.